Amniotics today announces the outcome of the exercise of warrants of series TO1
May 23, 2022
Amniotics AB (publ) (“Amniotics” or the “Company”) conducted a unit issue of shares and warrants of series TO1 (the “warrants”) in connection with the listing on Nasdaq First North Growth Market on July 6, 2021. The units issued in connection with the listing consisted of shares and warrants of series TO1 (the "warrants"). The exercise period for the warrants lasted from May 5, 2022, to May 19, 2022. No notifications have been made for the exercise of the warrants.
One (1) warrant entitled the holder to subscribe for one (1) new share in Amniotics at a subscription price set to 23.50 SEK. As the subscription price exceeds the prevailing share price, no notifications have been made for the exercise of the warrants.
Redeye AB acts as financial adviser and Nordic Issuing AB acts as the issuing agent in the Rights Issue.